BioCentury
ARTICLE | Strategy

Building a mAb Platform

Vivalis hopes to generate mAb pipeline, more partnerships via Humalex platform

July 12, 2010 7:00 AM UTC

For the last several years, Vivalis S.A. has been granting non-exclusive licenses to its EB66 cell line for production of vaccines and protein therapeutics. The company's acquisition of Humalys S.A.S. in January was designed to move the French biotech into antibody discovery, which it hoped to parlay into more lucrative exclusive deals. The first of these was announced last month with Sanofi Pasteur.

"We are now able to go from the discovery of the antibody through to Phase II clinical batch material," co-founder and CEO Franck Grimaud told BioCentury...